2016 Arizona Revised Statutes
Title 36 - Public Health and Safety
§ 36-2512 Substances in schedule I

START_STATUTE36-2512. Substances in schedule I

A. The following controlled substances, unless specifically excepted, are included in schedule I:

1. Any of the following, including opiates and their isomers, esters, ethers, salts and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

(a) Acetyl‑ alpha‑ methylfentanyl.

(b) Acetylmethadol.

(c) Allylprodine.

(d) Alphacetylmethadol, except levo‑ alphacetylmethadol or LAAM.

(e) Alphameprodine.

(f) Alphamethadol.

(g) Alpha‑ methylfentanyl.

(h) Alpha‑ methylthiofentanyl.

(i) Benzethidine.

(j) Betacetylmethadol.

(k) Beta‑ hydroxyfentanyl.

(l) Beta‑ hydroxy‑ 3‑ methylfentanyl.

(m) Betameprodine.

(n) Betamethadol.

(o) Betaprodine.

(p) Clonitazene.

(q) Dextromoramide.

(r) Diampromide.

(s) Diethylthiambutene.

(t) Difenoxin.

(u) Dimenoxadol.

(v) Dimepheptanol.

(w) Dimethylthiambutene.

(x) Dioxaphetyl butyrate.

(y) Dipipanone.

(z) Ethylmethylthiambutene.

(aa) Etonitazene.

(bb) Etoxeridine.

(cc) Furethidine.

(dd) Hydroxypethidine.

(ee) Ketobemidone.

(ff) Levomoramide.

(gg) Levophenacylmorphan.

(hh) 3‑ methylfentanyl.

(ii) 3‑ methylthiofentanyl.

(jj) Morpheridine.

(kk) MPPP(1‑ methyl‑ 4‑ phenyl‑ 4‑ propionoxypiperidine).

(ll) Noracymethadol.

(mm) Norlevorphanol.

(nn) Normethadone.

(oo) Norpipanone.

(pp) Para‑ fluorofentanyl.

(qq) PEPAP (1‑ (2‑ phenethyl)‑ 4‑ phenyl‑ 4‑ acetoxypiperidine).

(rr) Phenadoxone.

(ss) Phenampromide.

(tt) Phenomorphan.

(uu) Phenoperidine.

(vv) Piritramide.

(ww) Proheptazine.

(xx) Properidine.

(yy) Propiram.

(zz) Racemoramide.

(aaa) Thiofentanyl.

(bbb) Tilidine.

(ccc) Trimeperidine.

2. Any of the following opium derivatives and their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

(a) Acetorphine.

(b) Acetyldihydrocodeine.

(c) Benzylmorphine.

(d) Codeine methylbromide.

(e) Codeine‑ n‑ oxide.

(f) Cyprenorphine.

(g) Desomorphine.

(h) Dihydromorphine.

(i) Drotebanol.

(j) Etorphine, except hydrochloride salt.

(k) Heroin.

(l) Hydromorphinol.

(m) Methyldesorphine.

(n) Methyldihydromorphine.

(o) Morphine methylbromide.

(p) Morphine methylsulfonate.

(q) Morphine‑ n‑ oxide.

(r) Myrophine.

(s) Nicocodeine.

(t) Nicomorphine.

(u) Normorphine.

(v) Pholcodine.

(w) Thebacon.

3. Any material, compound, mixture or preparation that contains any quantity of the following hallucinogenic substances and their salts, isomers and salts of isomers, unless specifically excepted or unless listed in another schedule, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation (for the purposes of this paragraph, " isomer" includes the optical, position and geometric isomers):

(a) Alpha‑ ethyltryptamine (AET).

(b) 4‑ bromo‑ 2, 5‑ dimethoxyamphetamine.

(c) 4‑ bromo‑ 2, 5‑ dimethoxyphenethylamine (2C‑ B, Nexus).

(d) 2, 5‑ dimethoxyamphetamine.

(e) 2, 5-dimethoxy-4-ethylamphetamine (DOET).

(f) 2, 5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7).

(g) 4‑ methoxyamphetamine.

(h) 5‑ methoxy‑ 3, 4‑ methylenedioxyamphetamine.

(i) 4‑ methyl‑ 2, 5‑ dimethoxyamphetamine.

(j) 3, 4-methylenedioxy amphetamine.

(k) 3, 4‑ methylenedioxymethamphetamine (MDMA).

(l) 3, 4‑ methylenedioxy‑ N‑ ethylamphetamine (N-ethyl MDA, MDE, MDEA).

(m) N‑ hydroxy‑ 3, 4‑ methylenedioxyamphetamine (N-hydroxy MDA).

(n) 3, 4, 5‑ trimethoxy amphetamine.

(o) 5-methoxy-N, N, -dimethyltryptamine (5-MeO-DMT).

(p) Alpha-methyltryptamine (AMT).

(q) Bufotenine.

(r) Diethyltryptamine.

(s) Dimethyltryptamine.

(t) 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT).

(u) Ibogaine.

(v) Lysergic acid diethylamide.

(w) Cannabis, except the synthetic isomer of delta‑ 9‑ tetraydrocannabinol.

(x) Mescaline.

(y) Parahexyl.

(z) Peyote.

(aa) N‑ ethyl‑ 3‑ piperidyl benzilate.

(bb) N‑ methyl‑ 3‑ piperidyl benzilate.

(cc) Psilocybin.

(dd) Psilocyn.

(ee) Ethylamine analog of phencyclidine.

(ff) Pyrrolidine analog of phencyclidine.

(gg) 1‑ (1‑ (2‑ thienyl)cyclohexyl)pyrrolidine.

(hh) Thiophene analog of phencyclidine.

(ii) 4-methylmethcathinone (Mephedrone).

(jj) 3, 4-methylenedioxypyrovalerone (MDPV).

(kk) 2-(2, 5-dimethoxy-4-ethylphenyl)ethanamine (2C-E).

(ll) 2-(2, 5-dimethoxy-4-methylphenyl)ethanamine (2C-D).

(mm) 2-(4-chloro-2, 5-dimethoxyphenyl)ethanamine (2C-C).

(nn) 2-(4-iodo-2, 5-dimethoxyphenyl)ethanamine (2C-I).

(oo) 2-[4-(ethylthio)-2, 5-dimethoxyphenyl]ethanamine (2C-T-2).

(pp) 2-[4-(isopropylthio)-2, 5-dimethoxyphenyl]ethanamine (2C-T-4).

(qq) 2-(2, 5-dimethoxyphenyl)ethanamine (2C-H).

(rr) 2-(2, 5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N).

(ss) 2-(2, 5-dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P).

(tt) 3, 4, -methylenedioxy-N-methylcathinone (Methylone).

(uu) 2-(4-iodo-2, 5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe, Cimbi-5).

(vv) 2-(4-chloro-2, 5-dimethoxyphenyl)-N-(2- methoxybenzyl)ethanamine (25C-NBOMe, Cimbi-82).

(ww) 2‑ (4-bromo-2, 5-dimethoxyphenyl)‑ N‑ (2- methoxybenzyl)ethanamine (25B-NBOMe, Cimbi-36).

4. Any material, compound, mixture or preparation which contains any quantity of cannabimimetic substances and their salts, isomers, whether optical, positional or geometric, and salts of isomers, unless specifically excepted, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation. For the purposes of this subdivision, " cannabimimetic substances" means any substances within the following structural classes:

(a) 2‑ (3-hydroxycyclohexyl)phenol with substitution at the 5‑ position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent. Substances in the 2‑ (3‑ hydroxycyclohexyl)phenol generic definition include CP‑ 47, 497, CP‑ 47, 497 C8‑ Homolog, CP‑ 55, 940 and CP‑ 56, 667.

(b) 3-(naphthoyl)indole or 3-(naphthylmethane)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent. Substances in the 3‑ (naphthoyl)indole generic definition include AM-678, AM-2201, JWH-004, JWH‑ 007, JWH-009, JWH‑ 015, JWH-016, JWH-018, JWH-019, JWH-020, JWH-046, JWH‑ 047, JWH-048, JWH‑ 049, JWH-050, JWH-070, JWH-071, JWH-072, JWH-073, JWH‑ 076, JWH-079, JWH‑ 080, JWH-081, JWH-082, JWH-094, JWH-096, JWH-098, JWH‑ 116, JWH-120, JWH‑ 122, JWH-148, JWH-149, JWH-175, JWH-180, JWH-181, JWH‑ 182, JWH-184, JWH‑ 185, JWH-189, JWH-192, JWH-193, JWH-194, JWH-195, JWH‑ 196, JWH-197, JWH‑ 199, JWH-200, JWH-210, JWH-211, JWH-212, JWH-213, JWH‑ 234, JWH-235, JWH‑ 236, JWH-239, JWH-240, JWH-241, JWH-242, JWH-262, JWH‑ 386, JWH-387, JWH‑ 394, JWH-395, JWH-397, JWH-398, JWH-399, JWH-400, JWH‑ 412, JWH-413, JWH‑ 414 and JWH-415.

(c) 3-(naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent. Substances in the 3-(naphthoyl)pyrrole generic definition include JWH-030, JWH-145, JWH-146, JWH-147, JWH-150, JWH-156, JWH-243, JWH-244, JWH‑ 245, JWH‑ 246, JWH-292, JWH-293, JWH-307, JWH-308, JWH-346, JWH-348, JWH‑ 363, JWH‑ 364, JWH-365, JWH-367, JWH-368, JWH-369, JWH-370, JWH-371, JWH‑ 373 and JWH-392.

(d) 1-(naphthylmethylene)indene by substitution of the 3‑ position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent. Substances in the 1-(naphthylmethylene)indene generic definition include JWH‑ 176.

(e) 3-(phenylacetyl)indole or 3-(benzoyl)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent. Substances in the 3-(phenylacetyl)indole generic definition include AM-694, AM‑ 2233, JWH‑ 167, JWH‑ 201, JWH‑ 202, JWH‑ 203, JWH‑ 204, JWH‑ 205, JWH‑ 206, JWH‑ 207, JWH‑ 208, JWH‑ 209, JWH‑ 237, JWH‑ 248, JWH‑ 250, JWH‑ 251, JWH‑ 253, JWH‑ 302, JWH‑ 303, JWH‑ 304, JWH‑ 305, JWH‑ 306, JWH‑ 311, JWH‑ 312, JWH‑ 313, JWH‑ 314, JWH‑ 315, JWH‑ 316, RCS-4, RCS-8, SR‑ 18 and SR‑ 19.

(f) 3-(cyclopropylmethanone) indole or 3-(cyclobutylmethanone) indole or 3‑ (cyclopentylmethanone) indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl rings to any extent. Substances in the 3‑ (cyclopropylmethanone) indole generic definition include UR‑ 144, Fluoro‑ UR‑ 144 and XLR‑ 11.

(g) Other substances:

(i) (6ar, 10ar)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan2-yl)-6a, 7, 10, 10a‑ tetrahydrobenzo[c]chromen-1-ol) (HU-210).

(ii) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA, AKB48).

(iii) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB‑ 22).

(iv) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F‑ PB‑ 22).

(v) N‑ (1‑ amino‑ 3‑ methyl‑ 1‑ oxobutan‑ 2‑ yl)‑ 1‑ (4‑ fluorobenzyl)‑ 1H‑ indazole‑ 3‑ carboxamide (AB-FUBINACA).

(vi) N‑ (1‑ amino‑ 3, 3‑ dimethyl‑ 1‑ oxobutan‑ 2‑ yl)‑ 1‑ pentyl‑ 1H‑ indazole‑ 3‑ carboxamide (ADB-PINACA).

5. Any of the following substances having a depressant effect on the central nervous system, including their salts, isomers and salts of isomers, unless specifically excepted or listed in another schedule, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

(a) Mecloqualone.

(b) Methaqualone.

6. Gamma‑ hydroxybutyric acid, any salt, hydroxybutyric compound, derivative or preparation of gamma‑ hydroxybutyric acid, including any isomers, esters and ethers and salts of isomers, esters and ethers of gamma‑ hydroxybutyric acid, except gamma‑ butyrolactone if the existence of the isomers, esters and salts is possible within the specific chemical designation. Notwithstanding any other provision of the federal food, drug and cosmetic act, for purposes of security requirements imposed by law or regulation on registered distributors and registered manufacturers, this substance if manufactured, distributed or processed in accordance with an exemption approved under section 505 of the federal food, drug and cosmetic act is a controlled substance in schedule III pursuant to section 36‑ 2514.

7. Any of the following stimulants including their salts, isomers and salts of isomers, unless specifically excepted or listed in another schedule, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

(a) Alpha-methylaminovalerophenone (Pentedrone).

(b) Alpha-pyrrolidinobutiophenone (Alpha-PBP).

(c) Alpha-pyrrolidinopropiophenone (Alpha-PPP).

(d) Alpha-pyrrolidinovalerophenone (Alpha-PVP).

(e) Aminorex.

(f) N-benzylpiperazine (BZP).

(g) Beta-keto-n‑ methylbenzodioxolylbutanamine (Butylone).

(h) Beta-keto-n‑ methylbenzodioxolylpentanamine (Pentylone).

(i) Cathinomimetic substances which are any substances derived from cathinone, (2-amino-1-phenyl-1-propanone) by any substitution at the phenyl ring, any substitution at the 3 position, any substitution at the nitrogen atom or any combination of the above substitutions.

(j) (+)cis‑ 4‑ methylaminorex((+)cis‑ 4, 5‑ dihydro‑ 4‑ methyl‑ 5‑ phenyl-2-oxazolamine).

(k) Dihydro-5H-indeno-(5, 6-d)-1, 3-dioxol-6-amine) (MDAI).

(l) Dimethylcathinone (Metamfepramone).

(m) Ethcathinone.

(n) Fenethylline.

(o) 3‑ fluoro‑ N‑ methylcathinone (3-FMC).

(p) 4‑ fluoro‑ N‑ methylcathinone (4-FMC, Flephedrone).

(q) Methcathinone.

(r) Methoxy-alpha-pyrrolidinopropiophenone (MOPPP).

(s) Methoxyphenethylamine mimetic substances which are any substances derived from 2, 5-dimethoxy-phenethylamine by any substitution at the phenyl ring, any substitution at the nitrogen atom or any combination of the above substitutions.

(t) Methyl‑ a‑ pyrrolidinobutiophenone (MPBP).

(u) 4‑ methyl‑ alpha-pyrrolidinopropiophenone (4‑ MePPP).

(v) 4‑ methyl‑ N‑ ethylcathinone (4-MEC).

(w) Methylenedioxy‑ alphapyrrolidinopropiophenone (MDPPP).

(x) Methylenedioxyethcathinone (Ethylone).

(y) N‑ ethylamphetamine.

(z) Naphthypyrovalerone (Naphyrone).

(aa) N, N‑ dimethylamphetamine.

B. The board may except by rule any compound, mixture or preparation containing any substance listed in this section from the application of all or any part of this chapter if the compound, mixture or preparation contains one or more active medicinal ingredients and if the admixtures are included therein in combinations, quantity, proportion or concentration that vitiates the potential for abuse. END_STATUTE